News | 10 January 2022
Arch Pharmalabs signs agreement with Orchem Technologies to use SMB platform
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
The drug is priced at Rs 2000 for a course of 40 tablets
The brand is now available pan-India through their distribution partner
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
It is the generic version of molnupiravir
It has also been granted permission to conduct trials for booster dose
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Subscribe To Our Newsletter & Stay Updated
